Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ter Arkh ; 92(11): 17-23, 2020 Dec 26.
Artigo em Russo | MEDLINE | ID: mdl-33720599

RESUMO

AIM: In a retrospective study, we evaluated factors associated with the early development of septic shock in patients with severe COVID-19. MATERIALS AND METHODS: We collected medical records of the intensive care unit patients submitted by the local COVID-19 hospitals across Russia to the Federal Center for the Critical Care at the Sechenov First Moscow State Medical University (Sechenov University). Septic shock in crticially ill patients requiring mechanical ventilation was defined as a need in vasopressors to maintain blood pressure. RESULTS: We studied 1078 patients with severe COVID-19 who were admitted to the intensive care units for respiratory support. There were 611 males and 467 females. The mean age was 61.013.7 years. Five hundred twenty five medical records (48.7%) were received from the Moscow hospitals, 159 (14.7%) from the Moscow region, and 394 (36.5%) from the hospitals located in 58 regions of the Russian Federation. In 613 (56.9%) patients, diagnosis of SARS-CoV-2 infection was confirmed by PCR, and in the other cases it was established on the basis of the clinical picture and the results of the chest CT scan. Septic shock developed in 214 (19.9%) of 1078 patients. In the logistic regression model, the risk of septic shock in patients older than 50 years was higher than in patients of a younger age (OR 2.34; 95% CI 1.533.67; p0.0001). In patients with more severe SARS-CoV-2 infection, there was an increase in the prevalence of cardiovascular diseases, including coronary heart disease and atrial fibrillation, type 2 diabetes and malignant tumors. The risk of septic shock in patients with three or more concomitant diseases was higher than in patients without any concomitant chronic diseases (OR 1.76; 95% CI 1.762.70). CONCLUSION: The risk of septic shock in patients with acute respiratory distress syndrome induced by SARS-CoV-2 is higher in patients older than 50 years with concomitant diseases, although a severe course of the disease is also possible in younger patients without any concomitant disorders.


Assuntos
COVID-19 , Diabetes Mellitus Tipo 2 , Choque Séptico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Moscou/epidemiologia , Estudos Retrospectivos , Fatores de Risco , Federação Russa/epidemiologia , SARS-CoV-2 , Choque Séptico/diagnóstico , Choque Séptico/epidemiologia , Choque Séptico/etiologia
2.
Can J Microbiol ; 54(7): 577-87, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18641704

RESUMO

Previously, we isolated a strain of Bacillus that had antifungal activity and produced lytic enzymes with fungicidal potential. In the present study, we identified the bacterium as Paenibacillus ehimensis and further explored its antifungal properties. In liquid co-cultivation assays, P. ehimensis IB-X-b decreased biomass production of several pathogenic fungi by 45%-75%. The inhibition was accompanied by degradation of fungal cell walls and alterations in hyphal morphology. Residual medium from cultures of P. ehimensis IB-X-b inhibited fungal growth, indicating the inhibitors were secreted into the medium. Of the 2 major lytic enzymes, chitinases were only induced by chitin-containing substrates, whereas beta-1,3-glucanase showed steady levels in all carbon sources. Both purified chitinase and beta-1,3-glucanase degraded cell walls of macerated fungal mycelia, whereas only the latter also degraded cell walls of intact mycelia. The results indicate synergism between the antifungal action mechanisms of these enzymes in which beta-1,3-glucanase is the initiator of the cell wall hydrolysis, whereas the degradation process is reinforced by chitinases. Paenibacillus ehimensis IB-X-b has pronounced antifungal activity with a wide range of fungi and has potential as a biological control agent against plant pathogenic fungi.


Assuntos
Antifúngicos/farmacologia , Bacillus/enzimologia , Quitinases/farmacologia , Fungos/efeitos dos fármacos , Glucana 1,3-beta-Glucosidase/farmacologia , Microbiologia do Solo , Antibiose , Antifúngicos/isolamento & purificação , Antifúngicos/metabolismo , Bacillus/genética , Bacillus/isolamento & purificação , Bacillus/fisiologia , Proteínas de Bactérias/genética , Proteínas de Bactérias/isolamento & purificação , Proteínas de Bactérias/metabolismo , Proteínas de Bactérias/farmacologia , Parede Celular/efeitos dos fármacos , Quitinases/genética , Quitinases/isolamento & purificação , Quitinases/metabolismo , Fungos/crescimento & desenvolvimento , Glucana 1,3-beta-Glucosidase/genética , Glucana 1,3-beta-Glucosidase/isolamento & purificação , Glucana 1,3-beta-Glucosidase/metabolismo , Micélio/efeitos dos fármacos , Micélio/crescimento & desenvolvimento , Doenças das Plantas/microbiologia
3.
Prikl Biokhim Mikrobiol ; 38(1): 103-8, 2002.
Artigo em Russo | MEDLINE | ID: mdl-11852559

RESUMO

An assay of dextranase (EC 3.2.1.11) was developed by using Sephadex G-200 coupled with Remazol Brilliant Blue (RBB) as an insoluble substrate. The assay procedure included incubation of suspension of the colored substrate in buffer containing enzyme under study, removal of residual insoluble substrate, and measurement of the absorbance of supernatant fluid containing colored soluble hydrolysis products at 595 nm. The procedure was examined in the screening of dextranase-forming bacilli from the microbial collection of the Institute of Biology, Ufa Research Center, RAS.


Assuntos
Antraquinonas/química , Dextranase/análise , Corantes/química , Dextranos/química , Géis , Espectrofotometria , Especificidade por Substrato
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...